MedPath

Study of Efficacy of Induction Chemotherapy With Gemcitabine and Carboplatin for Operable Non-small-cell Lung Cancer Before Surgery

Phase 2
Conditions
Lung Neoplasms
Registration Number
NCT00563160
Lead Sponsor
Hospital Authority, Hong Kong
Brief Summary

To study the activity of chemotherapy with Gemzar-carboplatin in the preoperative setting for operable stages of non-small-cell lung cancer and to identify novel molecular markers correlated with chemosensitivity and prognosis

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Histologically or cytologically proven, newly diagnosed primary bronchogenic non-small cell lung cancer
  • Measurable or evaluable tumour on chest X-ray or CT scan.
  • No multiple ipsilateral or contralateral parenchymal tumours
  • Stage I(exceptT1N0),II,IIIa disease as shown by PET-CT
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
pathological response rate12 months
Secondary Outcome Measures
NameTimeMethod
progression-free survival18 months
overall survival18 months
quality of life measurements18 months

Trial Locations

Locations (1)

Queen Elizabeth Hospital

🇨🇳

Hong Kong, China

Queen Elizabeth Hospital
🇨🇳Hong Kong, China
Che Mun Poon, Dr
Sub Investigator
Chun Key Law, Dr
Sub Investigator
Roger Ngan, Dr
Sub Investigator
Chung Kong Kwan, Dr
Sub Investigator
Cheuk Kin Lo, Dr
Sub Investigator
Johnny Chan, Dr
Sub Investigator
TK Au Yong, Dr
Sub Investigator
Ting Lok Kwan, Dr
Sub Investigator
Stella Cheung, Dr
Sub Investigator
Timothy Yip
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.